Embryo-lethal and teratogenic effect of the new platinum compound DPR in pregnant mice

Emanuela Ognio, Maddalena Lapide, Massimo Ottone, Václav Mandys, Miroslav Peterka, Brunella Parodi, Maurizio Viale

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Embryo-lethal and teratogenic effects caused by the cisplatin-procaine complex csi-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N 4-chloride-platinum(II) monohydrochloride monohydrate (DPR) were examined in CD-1 mice after a single administration of 7, 14, 21 or 28 mg/kg, injected on day 6, 9, 13 or 16 of pregnancy. At day 18 of pregnancy fetuses were removed and carefully examined for external, visceral and skeletal malformations under a dissecting microscope. A significant reduction of maternal weight gain was observed in pregnant mice after the administration of 21 (day 13) or 28 mg/kg (days 9 and 13) DPR. The exposure to DPR during the organogenesis and early histogenesis periods of prenatal development (administration on day 9 or 13) induced a significant reduction of the mean percentage of live fetuses and a significant increase of the mean percentage of dead and resorbed fetuses. A dose-dependent reduction of fetal body weight was observed in surviving specimens exposed to DPR on embryonic day 9, 13 or 16. The analysis of surviving fetuses killed on day 18 of gestation showed that a few, but statistically significant, external malformations and visceral anomalies were observed after administration of 21 or 28 mg/kg DPR on embryonic day 13. External malformations consisted of three hepato-omphalocele and six palatoschisis (one random palatoschisis was also observed at 21 mg/kg DPR given on day 9), while visceral anomalies included only renal pelvis dilatation. Skeletal anomalies affected fetuses independently of the day of treatment and were more frequent at the highest doses of DPR. They consisted of a delay in skull ossifications, vertebral and sternal anomalies, and formation of extra ribs. A low and non-significant incidence of skeletal malformations (assymetric sternum) was noticed in fetuses. Our data demonstrated that DPR can cause embryo toxic effects if administered during the period of organogenesis and early histogenesis. Beside embryolethality, DPR induced growth retardation and malformations in surviving fetuses.

Original languageEnglish
Pages (from-to)584-590
Number of pages7
JournalArchives of Toxicology
Volume77
Issue number10
DOIs
Publication statusPublished - Oct 2003

Fingerprint

Platinum Compounds
Fetus
Embryonic Structures
Organogenesis
Poisons
Benzoates
Pregnancy
Microscopes
Umbilical Hernia
Sternum
Fetal Weight
Kidney Pelvis
Ribs
Osteogenesis
Skull
Weight Gain
Dilatation
Mothers
Incidence
Growth

Keywords

  • DPR
  • Embryotoxicity
  • Mouse
  • Teratogenicity

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Embryo-lethal and teratogenic effect of the new platinum compound DPR in pregnant mice. / Ognio, Emanuela; Lapide, Maddalena; Ottone, Massimo; Mandys, Václav; Peterka, Miroslav; Parodi, Brunella; Viale, Maurizio.

In: Archives of Toxicology, Vol. 77, No. 10, 10.2003, p. 584-590.

Research output: Contribution to journalArticle

Ognio, E, Lapide, M, Ottone, M, Mandys, V, Peterka, M, Parodi, B & Viale, M 2003, 'Embryo-lethal and teratogenic effect of the new platinum compound DPR in pregnant mice', Archives of Toxicology, vol. 77, no. 10, pp. 584-590. https://doi.org/10.1007/s00204-003-0494-3
Ognio, Emanuela ; Lapide, Maddalena ; Ottone, Massimo ; Mandys, Václav ; Peterka, Miroslav ; Parodi, Brunella ; Viale, Maurizio. / Embryo-lethal and teratogenic effect of the new platinum compound DPR in pregnant mice. In: Archives of Toxicology. 2003 ; Vol. 77, No. 10. pp. 584-590.
@article{2adb2ba95f834f4b95e858a30a4b3981,
title = "Embryo-lethal and teratogenic effect of the new platinum compound DPR in pregnant mice",
abstract = "Embryo-lethal and teratogenic effects caused by the cisplatin-procaine complex csi-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N 4-chloride-platinum(II) monohydrochloride monohydrate (DPR) were examined in CD-1 mice after a single administration of 7, 14, 21 or 28 mg/kg, injected on day 6, 9, 13 or 16 of pregnancy. At day 18 of pregnancy fetuses were removed and carefully examined for external, visceral and skeletal malformations under a dissecting microscope. A significant reduction of maternal weight gain was observed in pregnant mice after the administration of 21 (day 13) or 28 mg/kg (days 9 and 13) DPR. The exposure to DPR during the organogenesis and early histogenesis periods of prenatal development (administration on day 9 or 13) induced a significant reduction of the mean percentage of live fetuses and a significant increase of the mean percentage of dead and resorbed fetuses. A dose-dependent reduction of fetal body weight was observed in surviving specimens exposed to DPR on embryonic day 9, 13 or 16. The analysis of surviving fetuses killed on day 18 of gestation showed that a few, but statistically significant, external malformations and visceral anomalies were observed after administration of 21 or 28 mg/kg DPR on embryonic day 13. External malformations consisted of three hepato-omphalocele and six palatoschisis (one random palatoschisis was also observed at 21 mg/kg DPR given on day 9), while visceral anomalies included only renal pelvis dilatation. Skeletal anomalies affected fetuses independently of the day of treatment and were more frequent at the highest doses of DPR. They consisted of a delay in skull ossifications, vertebral and sternal anomalies, and formation of extra ribs. A low and non-significant incidence of skeletal malformations (assymetric sternum) was noticed in fetuses. Our data demonstrated that DPR can cause embryo toxic effects if administered during the period of organogenesis and early histogenesis. Beside embryolethality, DPR induced growth retardation and malformations in surviving fetuses.",
keywords = "DPR, Embryotoxicity, Mouse, Teratogenicity",
author = "Emanuela Ognio and Maddalena Lapide and Massimo Ottone and V{\'a}clav Mandys and Miroslav Peterka and Brunella Parodi and Maurizio Viale",
year = "2003",
month = "10",
doi = "10.1007/s00204-003-0494-3",
language = "English",
volume = "77",
pages = "584--590",
journal = "Archiv fur Toxikologie",
issn = "0003-9446",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Embryo-lethal and teratogenic effect of the new platinum compound DPR in pregnant mice

AU - Ognio, Emanuela

AU - Lapide, Maddalena

AU - Ottone, Massimo

AU - Mandys, Václav

AU - Peterka, Miroslav

AU - Parodi, Brunella

AU - Viale, Maurizio

PY - 2003/10

Y1 - 2003/10

N2 - Embryo-lethal and teratogenic effects caused by the cisplatin-procaine complex csi-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N 4-chloride-platinum(II) monohydrochloride monohydrate (DPR) were examined in CD-1 mice after a single administration of 7, 14, 21 or 28 mg/kg, injected on day 6, 9, 13 or 16 of pregnancy. At day 18 of pregnancy fetuses were removed and carefully examined for external, visceral and skeletal malformations under a dissecting microscope. A significant reduction of maternal weight gain was observed in pregnant mice after the administration of 21 (day 13) or 28 mg/kg (days 9 and 13) DPR. The exposure to DPR during the organogenesis and early histogenesis periods of prenatal development (administration on day 9 or 13) induced a significant reduction of the mean percentage of live fetuses and a significant increase of the mean percentage of dead and resorbed fetuses. A dose-dependent reduction of fetal body weight was observed in surviving specimens exposed to DPR on embryonic day 9, 13 or 16. The analysis of surviving fetuses killed on day 18 of gestation showed that a few, but statistically significant, external malformations and visceral anomalies were observed after administration of 21 or 28 mg/kg DPR on embryonic day 13. External malformations consisted of three hepato-omphalocele and six palatoschisis (one random palatoschisis was also observed at 21 mg/kg DPR given on day 9), while visceral anomalies included only renal pelvis dilatation. Skeletal anomalies affected fetuses independently of the day of treatment and were more frequent at the highest doses of DPR. They consisted of a delay in skull ossifications, vertebral and sternal anomalies, and formation of extra ribs. A low and non-significant incidence of skeletal malformations (assymetric sternum) was noticed in fetuses. Our data demonstrated that DPR can cause embryo toxic effects if administered during the period of organogenesis and early histogenesis. Beside embryolethality, DPR induced growth retardation and malformations in surviving fetuses.

AB - Embryo-lethal and teratogenic effects caused by the cisplatin-procaine complex csi-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N 4-chloride-platinum(II) monohydrochloride monohydrate (DPR) were examined in CD-1 mice after a single administration of 7, 14, 21 or 28 mg/kg, injected on day 6, 9, 13 or 16 of pregnancy. At day 18 of pregnancy fetuses were removed and carefully examined for external, visceral and skeletal malformations under a dissecting microscope. A significant reduction of maternal weight gain was observed in pregnant mice after the administration of 21 (day 13) or 28 mg/kg (days 9 and 13) DPR. The exposure to DPR during the organogenesis and early histogenesis periods of prenatal development (administration on day 9 or 13) induced a significant reduction of the mean percentage of live fetuses and a significant increase of the mean percentage of dead and resorbed fetuses. A dose-dependent reduction of fetal body weight was observed in surviving specimens exposed to DPR on embryonic day 9, 13 or 16. The analysis of surviving fetuses killed on day 18 of gestation showed that a few, but statistically significant, external malformations and visceral anomalies were observed after administration of 21 or 28 mg/kg DPR on embryonic day 13. External malformations consisted of three hepato-omphalocele and six palatoschisis (one random palatoschisis was also observed at 21 mg/kg DPR given on day 9), while visceral anomalies included only renal pelvis dilatation. Skeletal anomalies affected fetuses independently of the day of treatment and were more frequent at the highest doses of DPR. They consisted of a delay in skull ossifications, vertebral and sternal anomalies, and formation of extra ribs. A low and non-significant incidence of skeletal malformations (assymetric sternum) was noticed in fetuses. Our data demonstrated that DPR can cause embryo toxic effects if administered during the period of organogenesis and early histogenesis. Beside embryolethality, DPR induced growth retardation and malformations in surviving fetuses.

KW - DPR

KW - Embryotoxicity

KW - Mouse

KW - Teratogenicity

UR - http://www.scopus.com/inward/record.url?scp=0242551871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242551871&partnerID=8YFLogxK

U2 - 10.1007/s00204-003-0494-3

DO - 10.1007/s00204-003-0494-3

M3 - Article

C2 - 14574446

AN - SCOPUS:0242551871

VL - 77

SP - 584

EP - 590

JO - Archiv fur Toxikologie

JF - Archiv fur Toxikologie

SN - 0003-9446

IS - 10

ER -